Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Returning 1152 results

Notice of Change to Eligible Activity Codes for NOT-NS-20-051 "Notice of Special Interest: Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System"

NOT
Wednesday, May 27, 2020
Sunday, January 1, 2023
NOT-NS-20-074

Funding Opportunity Purpose

Notice Change Eligible Activity Codes NOT-NS-20-051 Notice Special Interest: Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System" Notice Number: NOT-NS-20-074 Key Dates Release Date: 27, 2020 Related Announcements NOT-NS-20-051 - Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement Clinical Trial Optional) Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the eligible activity codes NOT-NS-20-051 "Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System". Effective immediately,the RF1 activity codewill added an eligible activity codeto NOT-NS-20-051, applications submitted both, PA-18-591 "Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) " PA-18-935 "Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional)". changes below bold italics. Currently Reads: Purpose Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 Parent Admin Supp Clinical Trial Optional). Eligible activity codes limited the mechanisms listed PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications PA-18-935 limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Modified Read: Purpose Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 Parent Admin Supp Clinical Trial Optional). Eligible activity codes limited the mechanisms listed PA-18-591, addition the RF1 mechanism. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications PA-18-935 limited the following mechanisms: P01, P50, RF1, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3) other aspects this Notice Special Interest remain unchanged. Inquiries Please direct inquiries to: Please contact program officer your active award.

Request for Information (RFI) on Developing an Online Educational Resource for Training in the Principles of Rigorous Research

NOT
Wednesday, May 13, 2020
Sunday, January 1, 2023
NOT-NS-20-062

Funding Opportunity Purpose

Request Information RFI) Developing Online Educational Resource Training the Principles Rigorous Research Notice Number: NOT-NS-20-062 Key Dates Release Date: 13, 2020 Response Date: August 01, 2020 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Request Information RFI) to solicit public input the best approaches providing accessible education the principles rigorous biomedical research members the scientific community. Rigorous research practices transparent reporting methods results vital the process scientific validation. way improve practice to improve training the principles rigorous research all career stages. an online educational resource be successful, should accessible, effective, adaptable, are attributes can implemented using variety approaches. especially encourage experts training, rigorous experimental design implementation, mentoring, education, technology contribute this RFI. Background Rigorous experimental design conduct, conjunction transparent reporting, vital appropriate validity interpretation scientific results. Training the fundamental principles rigorous research how implement rigorous experimental design reporting essential the scientific enterprise. Such principles include, are limited to, consideration experimenter biases, confounding factors, clearly defined assumptions, descriptions uncertainty, proper interpretation, full disclosure how data collected analyzed. this reason, National Institute Neurological Disorders Stroke NINDS) held workshop how best instill fundamental principles rigorous research. resulting publication this workshop suggests improved training all career stages better engagement all members the scientific community needed change culture science around issues rigor transparency. discussed this paper, any educational resource addressing issue need be freely available, easily discoverable, engaging, modular, adaptable, upgradeable. will also need use most effective teaching principles techniques, including expressing relevance, building self-efficacy, assessing behavioral change the end-user. NINDS created website facilitate efforts identify current online educational resources these topics. Participation various sectors the scientific enterprise be necessary improve training change culture, this website also describes effort bring scientists together collaborate such issues. NINDS seeking broader input the content format best conveying principles rigorous research the scientific community well effective ways encourage uptake dissemination these principles. encourage collaboration between scientists educational experts responding this RFI. Information Requested NINDS requests public input best practices innovative ideas education the principles rigorous research well promotion rigorous research practices. Responses especially encouraged the following questions: are most important principles rigorous research all scientists understand? each career stage undergraduates, graduates, post-docs, faculty), are best teaching practices use i.e. to convey information a lasting impactful way)? each career stage, is ideal delivery structure how often should principles reinforced? delivered an online resource, is most effective balance between different educational media e.g. text, video, interactive activities)? to Submit Response may respond this RFI filling this webform submitting email RigorChampions@nih.gov August 1, 2020. submitting email, please include Notice number NOT-NS-20-062) the subject line. Responding this RFI voluntary. Responses address any all aspects the information requested other relevant topics pertinent consideration NINDS. NINDS staff use discretion considering responses submitted after comment period closed. Respondents not receive individualized feedback concerning responses. Proprietary, classified, confidential, sensitive information should be included your response. Government reserves right use non-proprietary technical information any resultant solicitation(s), summaries, other materials. RFI for information planning purposes only should be construed a policy, solicitation applications, an obligation the part the Federal Government, National Institutes Health, NINDS provide support any ideas identified response it. Please note NINDS does intend make any awards based responses this RFI to otherwise pay the preparation any information submitted for Government's of such information. Inquiries Please direct inquiries to: Devon Crawford, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1917 Email: devon.crawford@nih.gov

Notice of Change to Research Strategy for RFA-NS-20-016 "Biological Measures for Prognosing and Monitoring of Persistent Concussive Symptoms in Early and Middle Adolescents: Center Without Walls (PCS-EMA CWOW) (U54 Clinical Trial Not Allowed)"

NOT
Tuesday, May 12, 2020
Sunday, January 1, 2023
NOT-NS-20-052

Funding Opportunity Purpose

Notice Change Research Strategy RFA-NS-20-016 Biological Measures Prognosing Monitoring Persistent Concussive Symptoms Early Middle Adolescents: Center Without Walls PCS-EMA CWOW) U54 Clinical Trial Allowed)" Notice Number: NOT-NS-20-052 Key Dates Release Date: 12, 2020 Related Announcements RFA-NS-20-016 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform potential applicants a change the Research Objectives Research Strategy RFA-NS-20-016 "Biological Measures Prognosing Monitoring Persistent Concussive Symptoms Early Middle Adolescents: Center Without Walls PCS-EMA CWOW) U54 Clinical Trial Allowed)." change be effective the June 26, 2020 receipt date. Changes shown bold italics below. Currently Reads: Part 2. Full Text Announcement Section I. Funding Opportunity Description Specific Research Objectives FOA solicits multicenter applications multidisciplinary groups order develop, then perform initial clinical validation objective biological measures improve accuracy prognosticating / monitoring persistent concussive symptoms result concussion and/or repetitive head impacts adolescent populations. overarching goal this program to develop validate biological measures will improve prognosis persistent concussive symptoms EMA patients accounts and sensitive individual variability symptom presentation. scientific project must include three parts: 1) development phase, 2) initial clinical validation phase, 3) description how validated biological measures be incorporated a risk stratification algorithm persistent concussive symptoms. Development phase: the development stage, research project should focus determining sensitivity specificity one more biological measures prognosing and/or monitoring persistent concussive symptoms an EMA population. Where feasible, biological measure should collected across research sites. Initial clinical validation phase: new independent cohort must recruited tested the full set biological measurements be validated using parameters context use obtained the development phase. Part 2. Full Text Announcement Section IV. Application Submission Information Overall Component PHS 398 Research Plan Overall) Research Strategy: Overall Research Strategy should describe PCS-EMA CWOW's goals objectives, background information, the overall importance including biological measures the prognosis monitoring persistent concussive symptoms an adolescent population. Describe rationale the proposed program how site uniquely positioned contribute world-class expertise cutting-edge resources towards addressing aims. Describe rationale choosing biological measure combination biological measures including feasibility use clinical settings future clinical trials. Describe need any proposed research cores how will interact the projects the Administrative core. Explain strategy achieving goals defined the overall Center, the research project research cores relate that strategy, a transition plan moving the development phase the initial clinical validation the biological measures a risk stratification algorithm. Clearly describe context(s) under the biological measure(s) be used. context(s) description should include is limited to: point care, clinical presentation the population e.g. patient groups specific concussive symptom clusters), mechanism injury. biological measures risk stratification algorithm should practical, efficient, implementable the appropriate clinical settings where patients present; e.g., emergency departments, urgent care clinics, sports medicine clinics, primary care offices. Describe plan developing a resource the broader research community including policies access collaborations. Describe the data sharing resource developed this Center serve accelerate research knowledge persistent concussive symptoms adolescents. Modified Read: Part 2. Full Text Announcement Section I. Funding Opportunity Description Specific Research Objectives FOA solicits multicenter applications multidisciplinary groups order develop, then perform initial clinical validation three more objective biological measures improve accuracy prognosticating / monitoring persistent concussive symptoms result concussion and/or repetitive head impacts adolescent populations. overarching goal this program to develop validate biological measures will improve prognosis persistent concussive symptoms EMA patients accounts and sensitive individual variability symptom presentation. scientific project must include three parts: 1) development phase, 2) initial clinical validation phase, 3) description how validated biological measures be incorporated a risk stratification algorithm persistent concussive symptoms. Development phase: the development stage, research project should focus determining sensitivity specificity each the biological measures specific combinations the biological measures prognosing and/or monitoring persistent concussive symptoms an EMA population. Where feasible, biological measure should collected across research sites. Initial clinical validation phase: new independent cohort must recruited tested the full set biological measurements be validated using parameters context use obtained the development phase. Part 2. Full Text Announcement Section IV. Application Submission Information Overall Component PHS 398 Research Plan Overall) Research Strategy: Overall Research Strategy should describe PCS-EMA CWOW's goals objectives, background information, the overall importance including biological measures the prognosis monitoring persistent concussive symptoms an adolescent population. Describe rationale the proposed program how site uniquely positioned contribute world-class expertise cutting-edge resources towards addressing aims. Describe rationale choosing of biological measures combination biological measures including feasibility use clinical settings future clinical trials. Describe need any proposed research cores how will interact the projects the Administrative core. Explain strategy achieving goals defined the overall Center, the research project research cores relate that strategy, a transition plan moving the development phase the initial clinical validation the biological measures a risk stratification algorithm. Clearly describe context(s) under the biological measure(s) be used. context(s) description should include is limited to: point care, clinical presentation the population e.g. patient groups specific concussive symptom clusters), mechanism injury. biological measures risk stratification algorithm should practical, efficient, implementable the appropriate clinical settings where patients present; e.g., emergency departments, urgent care clinics, sports medicine clinics, primary care offices. Describe plan developing a resource the broader research community including policies access collaborations. Describe the data sharing resource developed this Center serve accelerate research knowledge persistent concussive symptoms adolescents. aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Patrick SF Bellgowan, Ph.D. Repair Plasticity Cluster, National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1447 Email: psfb@mail.nih.gov

Notice to Extend RFA-MH-20-120 BRAIN Initiative: Secondary Analysis and Archiving of BRAIN Initiative Data (R01 Clinical Trial Not Allowed)

NOT
Monday, May 11, 2020
Sunday, January 1, 2023
NOT-MH-20-052

Funding Opportunity Purpose

Notice Extend RFA-MH-20-120 BRAIN Initiative: Secondary Analysis Archiving BRAIN Initiative Data R01 Clinical Trial Allowed) Notice Number: NOT-MH-20-052 Key Dates Release Date: 11, 2020 Related Announcements RFA-MH-20-120 Issued National Institute Mental Health NIMH) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Drug Abuse NIDA) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH) Purpose purpose this Notice to extend RFA-MH-20-120, BRAIN Initiative: Non-Invasive Neuromodulation - New Tools Techniques Spatiotemporal Precision R01 Clinical Trial Optional) Part 1. Overview Information Key Dates Currently reads: Application Due Date(s) September 6, 2019 June 11, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Applicable Scientific Merit Review: March 2020 October 2020 Advisory Council: 2020, January 2021 Earliest Start Date: July 2020, April 2021 Expiration Date: June 12, 2020 Modified read: Application Due Date(s) September 6, 2019, June 11, 2020, February 26, 2021 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. late applications be accepted this Funding Opportunity Announcement. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Applicable Scientific Merit Review March 2020 October 2020, June 2021 Advisory Council 2020, January 2021, August 2021 Earliest Start Date July 2020, April 2021, September 2021 Expiration Date February 27, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Ming Zhan, Ph.D. National Institute Mental Health NIMH) Telephone: 301-827-3678 Email: ming.zhan@nih.gov

Notice of Additional Due Date and Additional Areas of Focus Especially of Interest of PAR-19-373 and PAR-19-384, "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)"

NOT
Thursday, May 7, 2020
Sunday, January 1, 2023
NOT-OD-20-103

Funding Opportunity Purpose

Notice Additional Due Date Additional Areas Focus Especially Interest” PAR-19-373 PAR-19-384, Research Biopsychosocial Factors Social Connectedness Isolation Health, Wellbeing, Illness, Recovery R01)" Notice Number: NOT-OD-20-103 Key Dates Release Date: 7, 2020 Related Announcements PAR-19-373 PAR-19-384 Issued NIH Basic Behavioral Social Science Opportunity Network OPPNET) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Institute Minority Health Health Disparities NIMHD) National Center Complementary Integrative Health NCCIH) applications this funding opportunity announcement should fall within mission the Institutes/Centers. following NIH Offices co-fund applications assigned those Institutes/Centers. Office Behavioral Social Sciences Research OBSSR) Purpose purpose this Notice to add third due date” additional areas focus especially interest” PAR-19-373 PAR-19-384 Research Biopsychosocial Factors Social Connectedness Isolation Health, Wellbeing, Illness, Recovery R01 Clinical Trials Allowed/Basic Experimental Studies Humans Required),” between two current due dates, March 17, 2020 March 17, 2021. Part 1 both PARs, under Key Dates, additional application due date June 8, 2020, added. I. Part 1 Key Dates PAR-19-373 PAR-19-384 Currently Reads: Application Due Date(s): March 17, 2020; March 17, 2021 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. II. Part 1 Key Dates PAR-19-373 PAR-19-384 Modified this Notice) Read italics): Application Due Date(s): March 17, 2020; June 8, 2020; March 17, 2021 Scientific Merit Review: June 2020, October 2020, June 2021 applications due 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due the listed date(s). Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review: June 2020, October 2020; June 2021 Advisory Council Review: August 2020, January 2021, August 2021 III. Part 1 Key Dates PAR-19-373 PAR-19-384 Remain Unmodified: Earliest Start Date September 2020 Expiration Date March 18, 2021 Part 1 both PARs, under Part 2, Section I. Funding Opportunity Description, of Three areas focus especially interest OppNet participating NIH ICO’s include, are limited to, those listed below” appear as, 1. Effects social connectedness, connection, isolation across lifespan Affective cognitive function during aging process Contextual factors increase mitigate impact disruption isolation different developmental time points, e.g., Caregivers people dementia, severe illness, end-of-life Chronic illness limited mobility Perceived strength quality extant social connections Recent diagnosis a serious medical illness Sleep changes across lifespan e.g. during adolescence, early parenthood, menopause) Molecular markers mechanisms e.g., epigenetic modifications, gene expression, microbiome alterations, telomere attrition) associated changes social connectedness Neurobiological developmental trajectories Protective and/or risk factors associated isolation connection disruption different times development over lifespan e.g., adolescence, death mate/parent, middle-age males, onset serious medical diagnosis) Aggressive behaviors and/or risky sexual activity associated connection trajectories Mechanisms connectedness, connection, isolation Neurobiological factors Impact structure function the nervous system central, peripheral, autonomic) Impact neuroimmune neuroendocrine systems Impact neural systems associated basic affective, cognitive, social processes Importance inter-individual neural synchrony mediating moderating effects relationship trajectories Neurobiological biosignatures predict sensitivity connection disruption isolation Neurobiological processes could targets ameliorate negative effects disruption isolation Neurophysiological consequences disruption isolation substance disorders SUDs) mental illness Behavioral environmental factors consequences perceived isolation e.g., loneliness) and/or objective/observed isolation behavioral clinical outcomes adolescence adulthood Connections between social disruption/isolation specific populations and/or health/illness contexts, e.g., Sex/gender differences; sexual gender minorities Racial/ethnic differences, acculturation/bicultural adaptations contributions social integration versus isolation Autism, HIV, mental illness, recovery status, substance disorder Whether source connection disruption leads different processes outcomes E.g., Self-induced isolation versus isolation others, sense undesired loneliness vs. sought solitude Modified this Notice) Read italics): 1. Effects social connectedness, connection, isolation across lifespan Affective cognitive function during aging process Contextual factors increase mitigate impact disruption isolation different developmental time points, e.g., Caregivers people COVID-19, dementia, severe illness, end-of-life Chronic illness limited mobility Perceived strength quality extant social connections Recent diagnosis a serious medical illness including, not limited to, COVID-19 Sleep changes across lifespan e.g. during adolescence, early parenthood, menopause) Molecular markers mechanisms e.g., epigenetic modifications, gene expression, microbiome alterations, telomere attrition) associated changes social connectedness Neurobiological developmental trajectories Protective and/or risk factors associated isolation connection disruption different times development over lifespan e.g., adolescence, death mate/parent, middle-age males, onset serious medical diagnosis) Aggressive behaviors and/or risky sexual activity associated connection trajectories Mechanisms connectedness, connection, isolation Neurobiological factors Impact structure function the nervous system central, peripheral, autonomic) Impact neuroimmune neuroendocrine systems Impact neural systems associated basic affective, cognitive, social processes Importance inter-individual neural synchrony mediating moderating effects relationship trajectories Neurobiological biosignatures predict sensitivity connection disruption isolation Neurobiological processes could targets ameliorate negative effects disruption isolation Neurophysiological consequences disruption isolation substance disorders SUDs) mental illness Behavioral environmental factors consequences perceived isolation e.g., loneliness) and/or objective/observed isolation behavioral clinical outcomes adolescence adulthood Connections between social disruption/isolation specific populations and/or health/illness contexts, e.g., Sex/gender differences; sexual gender minorities Racial/ethnic differences, acculturation/bicultural adaptations contributions social integration versus isolation Autism, COVID-19, HIV, mental illness, recovery status, substance disorder Whether source connection disruption leads different processes outcomes E.g., Self-induced isolation versus isolation others, sense undesired loneliness vs. sought solitude E.g., Isolation the result preventing COVID-19 a household, preventing COVID-19 infection within household NOTE: other aspects these funding opportunity announcements PAR-19-373 PAR-19-384) remain unchanged. Inquiries Please direct inquiries to: William Elwood, PhD Office Behavioral Social Sciences Research OBSSR) Telephone: 301-402-0116 Email: william.elwood@nih.gov

Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supp)

Notice of Special Interest
Thursday, May 7, 2020
Thursday, September 8, 2022
333
NOT-NS-20-024

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements the U.S.-Japan Brain Research Cooperative Program BRCP) - U.S. Entity Admin Supp) Notice Number: NOT-NS-20-024 Key Dates Release Date: 05, 2020 First Available Due Date: September 07, 2020 Expiration Date:September 08, 2022 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Center Complementary Integrative Health NCCIH) Purpose National Institutes Health NIH) announces continuation the U.S. entity the U.S.-Japan Brain Research Cooperative Program BRCP). administrative supplement program provide funds currently active research grants are currently supported one the participating NIH Institutes Centers. Notice soliciting administrative supplements the following mechanisms ONLY: DP1, DP2, DP5, R01, R03, R21, R33, R34, R37, R61, U01, UH2, and UH3. purpose the BRCP to promote scientist exchange, training, collaborations basic, translational clinical research between neuroscientists the U.S. Japan. U.S. entity the BRCP supports following activities: 1) Visit U.S. scientists conduct collaborative research and/or acquire advanced research skills Japanese institutions, 2) Joint workshops exchange scientific information to foster collaborations. Background agreement ldquo;Cooperation Research Development Science Technology” signed the President the United States the Prime Minister Japan May 1, 1980, has subsequently renewed extended. Under umbrella this Agreement, National Institute Neurological Disorders Stroke NINDS) the National Institute Physiological Sciences NIPS), Okazaki National Research Institutes, Japan, signed Memorandum Understanding a Brain Research Cooperative Program BRCP) November 29, 2000. Since inception the U.S. BRCP 2002, NIH successfully supported U.S. neuroscientists’ collaborative activities Japanese institutions, joint workshops the neurosciences. Japanese entity the BRCP been active since 2001. Details the program available http://www.nips.ac.jp/jusnou/english/. Within funding guidelines the BRCP program, country supports own scientists participate the aforementioned activities. BRCP Activities Supported the NIH A. Collaborative Research Fund Collaborative Research Fund provides support the travel lodging expenses the U.S. scientist’s visit Japan. visit the institution Japan be performed the PD/PI, collaborators, postdoctoral fellows students work the collaborative project. Support the Collaborative Research Fund be used one multiple trips. duration the supplement one year. supplement be carried over the next fiscal year, prior approval NIH Program staff. B. Workshop Fund U.S. Workshop Fund provides partial support joint workshops. U.S. Japan funding agencies the BRCP provide parallel support joint-workshops. entity support travel lodging expenses the joint-workshop participants their own country. the joint workshop be held the U.S., U.S. entity the BRCP support logistical meeting expenses. the joint workshop be held Japan, Japan entity support logistical meeting expenses. proposed workshop should at least co-organizer the U.S. one Japan. Co-organizers encouraged work together develop workshop applications. U.S. co-organizer must an active grant a participating NIH Institute Center. Workshop applications U.S. co-organizers should submitted response this FOA. Similarly, co-organizers Japan should submit application the NIPS. See: http://www.nips.ac.jp/jusnou/eng/ Applicants encouraged use Workshop Fund compensate travel lodging individuals groups are underrepresented the biomedical, clinical, behavioral social sciences encourage participation, the planning implementation of, well participation in, proposed workshop. NOT-OD--20-031. support junior investigators, postdoctoral fellows, graduate students also encouraged. Areas research interests the participating NIH Institutes Centers NINDS supports basic, translational clinical research understand structure function the nervous system mechanisms underlying neurological disorders stroke. Awardees projects funded the NIH BRAIN Initiative braininitiative.nih.gov/) encouraged submit supplement requests collaborative efforts are within scope this FOA NIH’s goals the BRAIN Initiative, defined the strategic planning report, BRAIN 2025: Scientific Vision. Investigators encouraged contact potential collaborators participating related efforts led Japan such the Brain/MINDS project http://brainminds.jp/en/). Collaborations promote interdisciplinary approaches research questions within NINDS mission also strongly encouraged. NIA supports broad spectrum research training aimed a better understanding age-related normal pathological changes the structure function the nervous system how such changes affect behavior. addition, NIA encourages cross-country collaborations research related the etiology, diagnosis, progression, treatment Alzheimer’s Disease AD). mission includes basic clinical studies the nervous system, clinical trials interventions therapeutic modalities, epidemiological research identify risk factors to establish prevalence incidence estimates pathologic conditions aging AD. mission NIBIB to improve human health leading development accelerating application biomedical technologies. NIBIB encourages submission applications support development bioengineering biomedical imaging technologies. NIDA supports basic, clinical, applied research the causes, consequences, prevention treatment drug abuse addiction. NIDCD encourages collaborative basic clinical biomedical bio-behavioral research the communication sciences hearing, balance, smell, taste, voice, speech language. NIDCR supports wide range basic, clinical translational research painful disorders the orofacial region including temporomandibular joint disorders, trigeminal neuropathies, burning mouth syndrome, oral cancer pain, dental pain, other conditions; well chronic pain conditions co-morbid orofacial pain. NIEHS supports basic mechanistic human based studies the interplay environmental neurotoxicant exposure neuronal dysfunction across life span. includes influence prenatal exposure both childhood adult dysfunction/disease well adult exposures the aging brain. NIMH supports research transform understanding treatment mental illnesses through basic, translational, clinical, services research, paving way prevention, recovery, cure. NIMH encourages innovative thinking ensure a full array novel scientific perspectives used further discovery the evolving science brain, behavior, experience. NIMH now focusing an experimental medicine approach evaluating novel interventions mental illnesses. strategy designed increase value the public investment early clinical trials ensuring informed, data-driven decisions an early stage behavioral, device, pharmacologic studies. NCCIH supports rigorous scientific investigation, usefulness safety complementary integrative health approaches, their roles improving health health care. includes collaborations involving studying neurobiological mechanisms natural products such herbs, prebiotics, probiotics, dietary supplements) mind body interventions such acupuncture, meditation, manual therapy, yoga, Tai Chi, hypnosis, music art therapy, etc) their effects pain, sleep, stress, anxiety, emotional well-being, and/or behavioral changes. NCATS supports development disruptive innovative methods technologies will enhance development, testing implementation diagnostics therapeutics across wide range human diseases conditions. includes translational early stage clinical research rare neurologic brain conditions. Award Project Period be eligible, parent award must active the current fiscal year i.e., parent award received funds the current fiscal year is in extension period), the research proposed the supplement should requested one year should accomplished within currently approved project period the existing parent award. awarding institute consider no-cost extension up an additional year the conclusion the first year. Award Budget Application budgets Collaborative Research Funds limited 25,000 direct cost. to 2,500 be used research supplies. Funds the BRCP not used salary support the PD/PI, collaborators, postdoctoral fellows, students collaborators. Travel costs associated Collaborative Research Fund requests should exceed U.S. Government Foreign Per Diem Rates Japan. See: http://aoprals.state.gov/content.asp?content_id=184&menu_id=81/ Application budgets Workshop Funds limited 35,000 direct cost. support travel lodging expenses should exceed U.S. Government Per Diem Rates http://www.gsa.gov/portal/content/101518 ; or http://aoprals.state.gov/content.asp?content_id=184&menu_id=81/ ). honorarium allowed. is recommended investigators secure additional funding support other sources, needed. announcement for supplements existing projects. research proposed the NIH grantee the supplement application must within original scope the NIH-supported grant award. Similarly, scope the proposed collaborative research activities workshops should well aligned the aims the parent award. Eligible Individuals Program Director/Principal Investigator) Individual(s) must hold active grant award one the participating NIH Institutes Centers. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) must submitted the awardee institution the parent award. New early stage investigators encouraged apply, well established neuroscientists. Individuals diverse backgrounds, including underrepresented racial ethnic groups, individuals disabilities, women always encouraged apply NIH support. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – September 7, 2020, September 7, 2021, September 7, 2022, 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-IC-20-024” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. Only existing awardees a participating Institute Center eligible apply. Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-F-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Page Limits: NIH consider supplements a Research Strategy no than 6 pages, addition the abstract. Research Strategies Collaborative Research Fund Submitted applications collaboration/training must include: Description the goals the collaboration/training how will enhance research the NIH-supported parent grant Details the supplement's specific aims, research design, methods data analysis Background significance the proposed research/training its relevance the goals the BRCP the mission the participating NIH Institutes Centers unique opportunities offered this collaboration/training, the reciprocal U.S. Japan) entity the project should clearly delineated Description the qualifications the Japanese host the research facilities resources the host institution Submitted applications collaboration/training must include letter invitation biosketch the Japanese host(s). Workshop Fund Submitted applications joint workshops must include: Description the importance the proposed workshop investigators the field the larger neuroscience community Relevance the workshop the goals the BRCP the mission the participating NIH Institutes Centers Background anticipated outcomes Description the meeting content, including topics, sessions, a tentative agenda Plans foster potential collaborations between U.S. Japanese participants Justification the proposed workshop location duration Composition role the organizing committee, the name credentials key participants i.e., presenters, moderators) Plans disseminate information generated the proposed workshop the larger scientific community. Plans the inclusion junior investigators, women, racial/ethnic minorities, persons disabilities. Review Process: Administrative supplement requests undergo administrative evaluation NIH Program staff the participating Institutes Centers. Reporting: Reporting requirements be specified the terms conditions award applicable the supplemental activities. most non-competing continuation applications, progress report budget the supplement must included with, clearly delineated from, progress report budget the parent award. progress report must include information the activities supported the supplement even support future years not requested. Final Report Within month the completion all collaborative research/training efforts workshops, U.S. BRCP supported investigators required submit final report the NIH, detailing following information: Project objectives Significance Results/findings including list publications, presentations, dissemination material research grant applications resulting the collaboration/training workshop Outcome collaboration/training workshop how benefits NIH supported research plans continued collaboration the Japanese investigator(s) Inquiries Please direct inquiries to: Scientific/Research Contact(s) Stacey D. ChambersNational Institute Neurological Disorders Stroke NINDS)Telephone: 301-496-0690 Email: chambers@ninds.nih.go Coryse St. Hillaire-Clarke, Ph.D.National Institute Aging NIA)Telephone: 301-827-6944Email: sthillaireclacn@mail.nih.gov Shumin Wang, Ph.D.National Institute Biomedical Imaging Bioengineering NIBIB)Telephone: 301-594-9001Email: shumin.wang@nih.gov Da-Yu Wu, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-1887 Email: wudy@nida.nih.gov Susan L. Sullivan, Ph.D.National Institute Deafness amp; Communication Disorders NIDCD)Telephone: 301-451-3841Email: sullivaS@nidcd.nih.gov Yolanda F. Vallejo, Ph.D.National Institute Dental Craniofacial Research NIDCR)Telephone: 301-827-4655Email: Yolanda.Vallejo@nih.gov Jonathan A. Hollander, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-9467 Email: jonathan.hollander@nih.gov Miri Gitik, Ph.D. National Institute Mental Health NIMH) Telephone: 301-827-3523 Email: miri.gitik@nih.gov Inna Belfer, M.D., Ph.D. National Center Complementary Integrative Health NCCIH) Telephone: 301-435-1573 Email: inna.belfer@nih.gov Danilo A. Tagle, Ph.D., M.S. National Center Advancing Translational Sciences NCATS) Telephone: 301-594-8064 Email: danilo.tagle@nih.gov Financial/Grants Management Contact(s) Chief Grants Management Officer National Institute Neurological Disorders Stroke NINDS) Email: ChiefGrantsManagementOfficer@ninds.nih.gov Jennifer Edwards National Institute Aging NIA) Telephone: 301-827-6689 Email: edwardsj@mail.nih.gov James Huff National Institute Biomedical Imaging Bioengineering NIBIB) Telephone: 301-451-4786 Email: huffj@mail.nih.gov Cheryl Nathaniel National Institute Drug Abuse NIDA) Telephone: 202-526-0108 Email: nathanic@nida.nih.gov Christopher MyersNational Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-402-0909 Email: myersc@mail.nih.gov Dede Rutberg National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4798 Email: rutbergd@mail.nih.gov James R. Williams National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-1403 Email: james.williams3@nih.gov Tamara KeesNational Institute Mental Health NIMH)Telephone: 301-443-8811Email: tkees@mail.nih.gov Shelley M. CarowNational Center Complementary Integrative Health NCCIH)Telephone: 301-594-3788Email: carows@mail.nih.gov Karen BrummettNational Center Advancing Translational Sciences NCATS)Telephone: 301-594-6268Email: Karen.Brummett@nih.gov

Notice of Change to Key Dates for PAR-18-421 "NINDS Program Project Grant (P01 Clinical Trial Optional)"

NOT
Wednesday, May 6, 2020
Sunday, January 1, 2023
NOT-NS-20-071

Funding Opportunity Purpose

Notice Change Key Dates PAR-18-421 NINDS Program Project Grant P01 Clinical Trial Optional)" Notice Number: NOT-NS-20-071 Key Dates Release Date: 6, 2020 Related Announcements PAR-18-421 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-421 "NINDS Program Project Grant P01 Clinical Trial Optional)" changes shown below bold italics). Funding Opportunity Announcement been extended one additional council round. dates been modified add following New Application Due Date: January 25, 2021 AIDS Application Due Date May 7, 2021. Currently Reads: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2021 Modified Read: Part 1. Overview Information Key Dates Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date 8, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: David Owens, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9248 Email: do47h@nih.gov

Notice of Change to Key Dates for PAR-18-721 "Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)"

NOT
Wednesday, May 6, 2020
CounterACT
Wednesday, July 1, 2020
NOT-NS-20-064

Funding Opportunity Purpose

Notice Change Key Dates PAR-18-721 Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed)" Notice Number: NOT-NS-20-064 Key Dates Release Date: 6, 2020 Related Announcements PAR-18-721 Issued National Institute Neurological Disorders Stroke NINDS) National Eye Institute NEI) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-721 "Countermeasures Against Chemical Threats CounterACT) Exploratory/Developmental Projects Translational Research R21 Clinical Trial Allowed)." Specifically, last receipt date been changed June 30, 2020 the new expiration date this FOA be July 1, 2020. Changes the FOA shown below bold italics. Currently Reads: Part 1. Overview Information Key Dates: Application Due Date(s) 30, 2018; 28, 2019; 26, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date 27, 2020 Modified Read: Part 1. Overview Information Key Dates: Application Due Date(s) 30, 2018; 28, 2019; June 30, 2020, 5:00 PM local time applicant organization. types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Expiration Date July 1, 2020 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Shardell Spriggs, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-443-8189 Email: shardell.spriggs@nih.gov

Notice of Change to Key Dates for PAR-18-468 "NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22-Clinical Trial Required)"

NOT
Tuesday, May 5, 2020
Sunday, January 1, 2023
NOT-NS-20-066

Funding Opportunity Purpose

Notice Change Key Dates PAR-18-468 NINDS Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research K22-Clinical Trial Required)" Notice Number: NOT-NS-20-066 Key Dates Release Date: 05, 2020 Related Announcements PAR-18-468 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-468 NINDS Advanced Postdoctoral Career Transition Award Promote Diversity Neuroscience Research K22-Clinical Trial Required)". funding opportunity announcements been extended one additional council round. dates been modified add following New Application Due Date: February 12, 2021, Resubmission Date: March 12, 2021, AIDS application Due Date: May 7, 2021. Currently Reads: Part 1. Overview Information Key Dates: Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2021 Modified Read: Part 1. Overview Information Key Dates: Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date 8, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-7966 Email: jonesmiche@ninds.nih.gov

Notice of Change to Key Dates for PAR-18-486 "NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)"

NOT
Tuesday, May 5, 2020
Sunday, January 1, 2023
NOT-NS-20-068

Funding Opportunity Purpose

Notice Change Key Dates PAR-18-486 NINDS Faculty Development Award Promote Diversity Neuroscience Research K01 Clinical Trial Required)" Notice Number: NOT-NS-20-068 Key Dates Release Date: 05, 2020 Related Announcements PAR-18-486 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants a change the Key Dates PAR-18-486 NINDS Faculty Development Award Promote Diversity Neuroscience Research K01 Clinical Trial Required)". funding opportunity announcement been extended one additional council round. dates been modified add following New Application Due Date: February 12, 2021, Resubmission Date: March 12, 2021, AIDS application Due Date: 7, 2021. Currently Reads: Part 1. Overview Information Key Dates: Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date January 8, 2021 Modified Read: Part 1. Overview Information Key Dates: Application Due Date(s) Standard dates apply, 5:00 PM local time applicant organization. All types non-AIDS applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. AIDS Application Due Date(s) Standard AIDS dates apply, 5:00 PM local time applicant organization. All types AIDS AIDS-related applications allowed this funding opportunity announcement due these dates. Applicants encouraged apply early allow adequate time make any corrections errors found the application during submission process the due date. Scientific Merit Review Standard dates apply Advisory Council Review Standard dates apply Earliest Start Date Standard dates apply Expiration Date 8, 2021 other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Michelle Jones-London, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-451-7966 Email: jonesmiche@ninds.nih.gov

Pages